Nasdaq24d
Greenwich LifeSciences Receives EMA Approval for Expanded Clinical Trial Sites in Europe for FLAMINGO-01 Study
Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...
Nasdaq24d
Greenwich LifeSciences Adds New Clinical Sites For FLAMINGO-01 Trial In Europe
(RTTNews) - Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, on Wednesday, announced that its application seeking expansion of its FLAMINGO-01 clinical trial in ...
Business Insider24d
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
The expansion of FLAMINGO-01 into Europe has been complimentary to the activated sites in the US, which also increased in 2024. In total we now have approximately 100 sites globally that are ...